Bellerophon Therapeutics ... (BLPH)
0.01
-0.01 (-47.37%)
At close: Dec 18, 2024, 5:51 PM
-47.37% (1D)
| Bid | n/a |
| Market Cap | 146.79K |
| Revenue (ttm) | 5.64M |
| Net Income (ttm) | -11.67M |
| EPS (ttm) | -0.89 |
| PE Ratio (ttm) | -0.01348314606741573 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 1,565 |
| Avg. Volume (20D) | 13,687 |
| Open | 0.01 |
| Previous Close | 0.02 |
| Day's Range | 0.01 - 0.01 |
| 52-Week Range | 0.01 - 0.10 |
| Beta | 0.70 |
About BLPH
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated w...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 13, 2015
Employees 18
Stock Exchange NASDAQ
Ticker Symbol BLPH
Website https://bellerophon.com